LEO Pharma A/S

ACTIVE

Ballerup, Copenhagen, Denmark, Capital Region of Denmark, 丹麦www.leo-pharma.comPrivate4,000 名员工成立于: 1908-01-01

隶属于 leo holding a/s (denmark)

Multinational Danish pharmaceutical company founded in 1908, developing and marketing products for dermatology, bone remodeling, thrombosis and coagulation across approximately 100 countries. Wholly owned by the LEO Foundation and not publicly listed.

概览

试验阶段分布

阶段

试验数

占比

2 期

42.9%

4 期

28.6%

1 期

14.3%

3 期

14.3%

试验状态分布

已完成

14.3%

尚未招募

14.3%

招募中

71.4%

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

EMA

European Medicines Agency

药物批准

PHILIPPINES

Philippines FDA

药物批准

NPRA

National Pharmaceutical Regulatory Agency

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

药物批准

近期批准

DAIVOBET 50 MICROGRAMOS/0,5 MG/G POMADA

CIMA_AEMPS

2026-06-05

FUCIBET 20 MG/G + 1 MG/G CREMA

ONE ALPHA CAPSULE 0.25MCG

NPRA

2025-11-28

ONE-ALPHA CAPSULES 0.5MCG

NPRA

2025-11-28

ONE-ALPHA CAPSULE 1MCG

NPRA

2025-11-28

Calcipotriol Ointment

NMPA

2025-10-22

Calcipotriol Ointment

NMPA

2025-10-22

FUCIBET 20 MG/G + 1 MG/G CREMA

CIMA_AEMPS

2025-08-28

资讯

Atopic Dermatitis Market Poised for Four-Fold Growth by 2034, Driven by Novel IL-13 Inhibitor Approvals

- The global atopic dermatitis market is projected to grow from USD 9.33 billion in 2024 to USD 38.07 billion by 2034, representing a compound annual growth rate of 15.10%. - LEO Pharma's tralokinumab-ldrm (Adbry) received FDA approval in December 2023 as the first interleukin-13 inhibitor for pediatric atopic dermatitis patients aged 12-17 years. - North America leads the market due to heightened patient awareness, robust healthcare infrastructure, and increased disease prevalence, with females showing higher prevalence rates (2.8%) compared to males (2.4%). - Market expansion is driven by regulatory approvals, novel treatment development, and rising healthcare expenditure alongside growing patient awareness of available therapeutic options.

Jul 23, 2025

返回机构列表

LEO Pharma A/S

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（7）

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants with Lichen Sclerosus

A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)

Tralokinumab monotherapy for children with moderate-to-severe atopic dermatitis.

A study in subjects with gout flares that investigates the effect, safety, tolerability, and pharmacokinetics (absorption, distribution, metabolism, and elimination) of a single dose of LEO 158968, a new compound that may potentially be used in the treatment of several autoinflammatory diseases

A 16-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g Compared to a Dummy Cream in Adult Subjects With Mild to Severe Palmoplantar Pustulosis

A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis.

Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight; ADJUST

药物批准

按机构分类的批准

近期批准

资讯

Atopic Dermatitis Market Poised for Four-Fold Growth by 2034, Driven by Novel IL-13 Inhibitor Approvals